163 related articles for article (PubMed ID: 33285035)
21. Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes.
Arenillas L; Calvo X; Luño E; Senent L; Alonso E; Ramos F; Ardanaz MT; Pedro C; Tormo M; Marco V; Montoro J; Díez-Campelo M; Brunet S; Arrizabalaga B; Xicoy B; Andreu R; Bonanad S; Jerez A; Nomdedeu B; Ferrer A; Sanz GF; Florensa L
J Clin Oncol; 2016 Sep; 34(27):3284-92. PubMed ID: 27382099
[TBL] [Abstract][Full Text] [Related]
22. Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre.
Huang H; Xu C; Gao J; Li B; Qin T; Xu Z; Ren S; Zhang Y; Jiao M; Qu S; Pan L; Hu N; Liu J; Cai W; Zhang Y; Wu D; Zhang P; Gale RP; Huang G; Zhou J; Shi L; Xiao Z
Blood Cancer J; 2020 Aug; 10(8):83. PubMed ID: 32801296
[TBL] [Abstract][Full Text] [Related]
23. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome.
Della Porta MG; Malcovati L; Invernizzi R; Travaglino E; Pascutto C; Maffioli M; Gallì A; Boggi S; Pietra D; Vanelli L; Marseglia C; Levi S; Arosio P; Lazzarino M; Cazzola M
Leukemia; 2006 Apr; 20(4):549-55. PubMed ID: 16498394
[TBL] [Abstract][Full Text] [Related]
24. The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50.
Uchida T; Hagihara M; Hua J; Inoue M
Leuk Res; 2017 Feb; 53():35-38. PubMed ID: 28013105
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic dysregulation of GATA1 is involved in myelodysplastic syndromes dyserythropoiesis.
Hopfer O; Nolte F; Mossner M; Komor M; Kmetsch A; Benslasfer O; Reissmann M; Nowak D; Hoelzer D; Thiel E; Hofmann WK
Eur J Haematol; 2012 Feb; 88(2):144-53. PubMed ID: 21967505
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic Value of Flow Cytometry Standardized Using the European LeukemiaNet for Myelodysplastic Syndrome.
Takeuchi A; Imataki O; Kubo H; Kondo A; Seo K; Uemura M; Yamaoka G; Murao K; Takeuchi A
Acta Haematol; 2020; 143(2):140-145. PubMed ID: 31330512
[TBL] [Abstract][Full Text] [Related]
27. [Expression of differentiation antigens on bone marrow myeloid cells of the patients with myelodysplastic syndromes and its clinical significances].
Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(10):672-7. PubMed ID: 20450725
[TBL] [Abstract][Full Text] [Related]
28. Striking dyserythropoiesis in a myelodysplastic syndrome.
Siow W; May PC; Haji R; Gabriel I; Bain BJ
Am J Hematol; 2017 Feb; 92(2):218. PubMed ID: 27601312
[No Abstract] [Full Text] [Related]
29. Flow cytometry in myelodysplastic syndrome: analysis of diagnostic utility using maturation pattern-based and quantitative approaches.
Chopra A; Pati H; Mahapatra M; Mishra P; Seth T; Kumar S; Singh S; Pandey S; Kumar R
Ann Hematol; 2012 Sep; 91(9):1351-62. PubMed ID: 22526362
[TBL] [Abstract][Full Text] [Related]
30. The impact of erythroblast enucleation efficiency on the severity of anemia in patients with myelodysplastic syndrome.
An C; Xue F; Sun L; Han H; Zhang Y; Hu Y
Cell Commun Signal; 2023 Nov; 21(1):332. PubMed ID: 37986081
[TBL] [Abstract][Full Text] [Related]
31. Serum erythropoietin and erythropoiesis in patients with myelodysplastic syndromes.
Bowen DT; Jacobs A; Cotes PM; Lewis TC
Eur J Haematol; 1990 Jan; 44(1):30-2. PubMed ID: 2307217
[TBL] [Abstract][Full Text] [Related]
32. Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.
Park S; Kosmider O; Maloisel F; Drenou B; Chapuis N; Lefebvre T; Karim Z; Puy H; Alary AS; Ducamp S; Verdier F; Bouilloux C; Rousseau A; Jacob MC; Debliquis A; Charpentier A; Gyan E; Anglaret B; Leyronnas C; Corm S; Slama B; Cheze S; Laribi K; Amé S; Rose C; Lachenal F; Toma A; Pica GM; Carre M; Garban F; Mariette C; Cahn JY; Meunier M; Herault O; Fenaux P; Wagner-Ballon O; Bardet V; Dreyfus F; Fontenay M
Haematologica; 2019 Mar; 104(3):497-504. PubMed ID: 30287621
[TBL] [Abstract][Full Text] [Related]
33. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients.
Matarraz S; López A; Barrena S; Fernandez C; Jensen E; Flores-Montero J; Rasillo A; Sayagues JM; Sánchez ML; Bárcena P; Hernandez-Rivas JM; Salvador C; Fernandez-Mosteirín N; Giralt M; Perdiguer L; Laranjeira P; Paiva A; Orfao A
Cytometry B Clin Cytom; 2010 May; 78(3):154-68. PubMed ID: 20198685
[TBL] [Abstract][Full Text] [Related]
34. "Bone marrow aspirate automated counts on hematology analyzers: formulating a scoring system based on hematology parameters, to discriminate reactive versus myelodysplastic syndrome-related bone marrows".
Tsagarakis NJ; Paterakis G; Papadhimitriou SI; Kritikou-Griva E; Goumakou E; Oudatzis G; Theodorakos I; Vasileiou P
Int J Lab Hematol; 2019 Aug; 41(4):542-549. PubMed ID: 31102331
[TBL] [Abstract][Full Text] [Related]
35. Analysis of Erythropoiesis Using Imaging Flow Cytometry.
Kalfa T; McGrath KE
Methods Mol Biol; 2018; 1698():175-192. PubMed ID: 29076090
[TBL] [Abstract][Full Text] [Related]
36. Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.
Westers TM; Cremers EM; Oelschlaegel U; Johansson U; Bettelheim P; Matarraz S; Orfao A; Moshaver B; Brodersen LE; Loken MR; Wells DA; Subirá D; Cullen M; Te Marvelde JG; van der Velden VH; Preijers FW; Chu SC; Feuillard J; Guérin E; Psarra K; Porwit A; Saft L; Ireland R; Milne T; Béné MC; Witte BI; Della Porta MG; Kern W; van de Loosdrecht AA;
Haematologica; 2017 Feb; 102(2):308-319. PubMed ID: 27758818
[TBL] [Abstract][Full Text] [Related]
37. Significance of fetal hemoglobin-containing erythroblasts (F blasts) and the F blast/F cell ratio in myelodysplastic syndromes.
Choi JW; Kim Y; Fujino M; Ito M
Leukemia; 2002 Aug; 16(8):1478-83. PubMed ID: 12145688
[TBL] [Abstract][Full Text] [Related]
38. Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes.
Frisan E; Vandekerckhove J; de Thonel A; Pierre-Eugène C; Sternberg A; Arlet JB; Floquet C; Gyan E; Kosmider O; Dreyfus F; Gabet AS; Courtois G; Vyas P; Ribeil JA; Zermati Y; Lacombe C; Mayeux P; Solary E; Garrido C; Hermine O; Fontenay M
Blood; 2012 Feb; 119(6):1532-42. PubMed ID: 22160620
[TBL] [Abstract][Full Text] [Related]
39. Disruption of erythroid nuclear opening and histone release in myelodysplastic syndromes.
Zhao B; Liu H; Mei Y; Liu Y; Han X; Yang J; Wickrema A; Ji P
Cancer Med; 2019 Mar; 8(3):1169-1174. PubMed ID: 30701702
[TBL] [Abstract][Full Text] [Related]
40. Artificial intelligence to empower diagnosis of myelodysplastic syndromes by multiparametric flow cytometry.
Clichet V; Lebon D; Chapuis N; Zhu J; Bardet V; Marolleau JP; Garçon L; Caulier A; Boyer T
Haematologica; 2023 Sep; 108(9):2435-2443. PubMed ID: 36924240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
